3 results match your criteria Clinical Medicine Reviews in Therapeutics [Journal]

  • Page 1 of 1

Raltegravir in HIV-1 infection: Safety and Efficacy in Treatment-naïve Patients.

Krishan K Pandey

Clin Med Rev Ther 2011 Dec;2012(4):13-30

1100 South Grand Boulevard, E. A. Doisy Research Center, Institute for Molecular Virology Saint Louis University Health Sciences Center, Saint Louis, MO 63104 USA.

The hunt for a compound which inhibits the HIV-1 integrase had been painstakingly difficult. Integrase is essential for viral replication as it mediates the integration of the viral DNA genome into the host DNA resulting in the establishment of the permanent provirus. Persistent efforts have resulted in the discovery of Raltegravir (Isentress, MK-0518), the first integrase inhibitor approved by US Food and Drug Administration for the treatment in HIV-1 infected patients. Read More

View Article

Download full-text PDF

http://dx.doi.org/10.4137/CMRT.S5022DOI Listing
December 2011
10 Reads

Ceftaroline: A New Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus (MRSA).

Clin Med Rev Ther 2011 Feb;3

Infectious Disease Division, Naval Medical Center San Diego, San Diego, CA United States.

Microbial resistance has reached alarming levels, threatening to outpace the ability to counter with more potent antimicrobial agents. In particular, methicillin-resistant Staphylococcus aureus (MRSA) has become a leading cause of skin and soft-tissue infections and PVL-positive strains have been associated with necrotizing pneumonia. Increasing reports of growing resistance to glycopeptides have been noted, further limiting the efficacy of standard antibiotics, such as vancomycin. Read More

View Article

Download full-text PDF

http://dx.doi.org/10.4137/CMRT.S1637DOI Listing
February 2011
25 Reads

Zidovudine and Lamivudine for HIV Infection.

Clin Med Rev Ther 2010 ;2:a2004

Department of Pharmaceutical Sciences at the University of Colorado Denver, Aurora, CO, USA.

Zidovudine and lamivudine (ZDV and 3TC) are long-standing nucleoside analog-reverse transcriptase inhibitors (NRTIs) with extensive clinical experience in a wide spectrum of patients from in utero through childhood and adult ages. The safety profiles of both drugs are well-known and side effects for ZDV most commonly include nausea/vomiting, fatigue, anemia/neutopenia, and lipoatrophy; while 3TC is well-tolerated. ZDV-3TC is currently a viable alternative NRTI backbone for initial three-drug therapy of HIV infection when tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) cannot be used because of a relative or absolute contraindication. Read More

View Article

Download full-text PDF

January 2010
15 Reads
  • Page 1 of 1